

**UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF ILLINOIS**

In re: TESTOSTERONE)	
REPLACEMENT THERAPY)	Case No. 14 CV 1748
PRODUCTS LIABILITY LITIGATION)	MDL No. 2545
)	

**JOINT MOTION FOR AN EXTENSION OF TIME FOR THE PARTIES TO FILE
THEIR PROPOSED CASE MANAGEMENT ORDERS**

Plaintiffs and Defendants respectfully move for an extension of time for the parties to file their proposed case management orders (“CMO”) as required in the Court’s February 1, 2018 minute order. *See* ECF No. 2354. In the order, the Court ordered the parties to confer and submit CMOs by February 16, 2018 for the submission of pretrial materials (1) in existing bellwether cases, and (2) for the CMO 75 cases and the CMO 87 “group 1” and “group 2” cases.

The parties request a one-week extension for the submission of pretrial materials in existing bellwether cases, moving the deadline from February 16 to February 23; and a two-week extension for the submission of pretrial materials for the CMO 75 and 87 cases, moving the deadline from February 16 to March 1. The parties do not seek to amend any other deadlines and this brief extension will not otherwise impact the schedule established by the Court.¹

Good cause exists for the requested extension. *See* Fed. R. Civ. Pro. 6(b)(1)(A) and 16(b)(4). The pretrial materials cover a number of things including motions in limine, deposition designations and objections, exhibit designations and objections, jury instructions, and voir dire questions. In addition, the parties are required to confer on proposals regarding supplementation

¹ The parties are not requesting an extension of time to submit the proposed CMO regarding “a plan to select and work up 100 Actavis cases for all pretrial purposes” required by the same minute order.

of expert reports and any other recurring trial-related issues. While the parties are currently attempting to gather all of this information, additional time is required to file the proposed CMOs.

For the foregoing reasons, the parties jointly request the Court grant the extension.

Dated: February 14, 2018

Respectfully Submitted,

/s/ Trent B. Miracle

Trent B. Miracle

Simmons Hanly Conroy LLP

One Court Street

Alton, IL 62002

Telephone: (618) 259-2222

Facsimile: (618) 259-2251

Email: tmiracle@simmonsfirm.com

Plaintiffs' Co-Lead Counsel

/s/ Michelle H. Yeary

Michelle Hart Yeary

Dechert LLP

902 Carnegie Center, Suite 500

Princeton, NJ 08540

Telephone: (609) 955-3200

Facsimile: (609) 955-3259

Email: michelle.yeary@dechert.com

*Attorney for AbbVie Inc. and Abbott
Laboratories*

Andrew K. Solow

Arnold & Porter

250 West 55th Street

New York, NY 10019

Telephone: (212) 836-7740

Facsimile: (212) 836-6776

Email: andrew.solow@arnoldporter.com

*Attorney for Endo Pharmaceuticals Inc. and
Auxilium Pharmaceuticals, Inc.*

Jeffrey D. Geoppinger

Ulmer & Berne LLP

600 Vine Street, Suite 2800

Cincinnati, OH 45202

Telephone: (513) 698-5000

Facsimile: (513) 698-5001

Email: jgeoppinger@ulmer.com

*Attorney for Actavis, Inc., Actavis Pharma,
Inc., Actavis Laboratories UT, Inc., and
Anda, Inc.*

CERTIFICATE OF SERVICE

I hereby certify that on February 14, 2018 the foregoing document was filed via the Court's CM/ECF system, which will automatically serve and send email notification of such filing to all registered attorneys of record.

/s/ Michelle H. Yeary
Michelle Hart Yeary